Running title: Physiological ferroxidase in biological fluid Character count for the title: 126 Character count for the running title: 45 Word count for abstract: 104 Word count for text (inc figure legends): 4175 Total number of references: 22 Total number of Tables/Figures: 5 ! 2 ABSTRACT Ferroxidase activity has been reported to be altered in various biological fluids in neurodegenerative disease, but the sources contributing to the altered activity are uncertain. Here we assay fractions of serum and cerebrospinal fluid with a newlyvalidated triplex ferroxidase assay. Our data indicate that while ceruloplasmin, a multicopper ferroxidase, is the predominant source of serum activity, activity in CSF predominantly derives from a <10kDa component, specifically from polyanions such as citrate and phosphate. We confirm that in human biological samples, ceruloplasmin activity in serum is decreased in AlzheimerÕs disease, but in CSF a reduction of activity in AlzheimerÕs disease originates from the polyanion component.
Iron is required as a cofactor in many metabolic processes. In aerobic conditions, the redox cycling between ferric (Fe 3+ ) and ferrous (Fe 2+ ) iron is controlled by protein chaperoning 1 to prevent the generation of reactive hydroxyl radicals 2 . Ferroxidase activity aerobically catalyses ferrous iron oxidation producing water, so mitigating hazardous reactive oxygen species (ROS) production 3 . Iron oxidation 2 , with subsequent Fe 3+ loading into extracellular transferrin (TF) 3, 4 , is important in cellular iron homeostasis by facilitating iron efflux through ferroportin (Fpn), the only known iron export pore protein.
In the brain, multicopper ceruloplasmin (CP) is considered the predominant ferroxidase for iron export. It is primarily secreted by choroid plexus epithelial cells, although there is also ceruloplasmin GPI-anchored to the astrocyte membranes 5 .
Some less-abundant multicopper proteins within the brain also have ferroxidase capability, such as hephaestin (HEPH), which is primarily expressed in oligodendrocytes 6 . The importance of ferroxidase activity in the central nervous system (CNS) has been demonstrated through ablation of CP in knockout mice and in aceruloplasminemia patients, where loss of function mutations of CP lead to brain regional iron retention and neurological deficits 7, 8 . Plasma CP can cross the blood brain barrier, and rescues neurological features in a mouse model of ParkinsonÕs disease (PD) 7 . Decreased CP oxidase activity has been reported in serum from patients suffering from AlzheimerÕs disease (AD) 9 and PD 10 .
The incorporation of iron into TF has been used to measure ferroxidase activity indirectly 4, 11 , but two main controversies on its accuracy arise from a reliance on nonphysiological (low) pH in order to suppress auto-oxidation, as well as the requirement for indirect colorimetric detection of holo-TF formation, which is a rate-limiting ! 4 extraneous step in appraising the enzyme kinetics 1 . A more direct measurement of ferroxidase activity is to assay Fe 2+ loss 12, 13 and Fe 3+ gain 12, 14 but buffer conditions are not physiological in these systems, and TF is absent. While each assay was originally used to determine activity in serum, they have been adapted increasingly to assay activity in other biological samples including human cerebrospinal fluid (CSF) [13] [14] [15] . To achieve measurement of ferroxidase activities under physiological conditions we recently developed a triplex ferroxidase assay that assesses ÔFerrous LossÕ, ÔFerric GainÕ and ÔTF LoadingÕ in tandem under biologically relevant pH and salinity. Here, we report the first assays of CSF and serum using this more physiologically appropriate system.
Human serum (0.25 mg/ml) was separated into filtrate (containing serum fluid, electrolytes, molecules and polypeptides <10kDa) and retentate (containing molecules and proteins >10kDa) fractions ( Fig. S1 ). Simultaneous measurement of ÔFerric GainÕ, ÔTF LoadingÕ and ÔFerrous LossÕ in human serum was determined in the presence or absence of apo-TF for all fractions (Fig. 1 ). Serum activity was achieved with all readouts from the triplex assay to provide the rate of total serum activity without TF as measured by ÔFerric GainÕ at 5.21 ± 0.28 µM Fe 3+ /min ( Fig. 1Ai ). As predicted 1 , the rate of oxidation was increased by the presence of TF in the TF loading assay (7.48 ± 0.31 µM Fe 3+ /min) ( Fig. 1Aii ). Most of the activity in total serum fractionated into the retentate (Ferric gain: 4.01 ± 0.16 µM Fe 3+ /min [77%], TF loading: 6.67 ± 0.20 µM Fe 3+ /min [89%]).
Multicopper ferroxidase inhibition with sodium azide 12 verified that CP was the major component of retentate activity (Fig. 1B) . However, despite all activity being ablated when using the Ferric Gain assay (Fig. 1Bi ), a small proportion of retentate activity ! 5 was not inhibited by azide when measured by TF loading (1.44 ± 0.13 µM Fe 3+ /min) ( Fig. 1Bii ). This is consistent with previous TF loading reports identifying the presence of a non-CP ferroxidase activity in serum 11, 17 . End point quantitation of Fe 2+ loss corroborated the production of Fe 3+ during the assays in both the presence and absence of TF (Fig. 1C ).
Triplex assay parameters for CSF were found to be as previously determined for purified CP 1 and human serum ( Fig. 1 ), at an optimal CSF volume of 20 µl (Fig.   S2B ). In contrast to serum fractions ( Fig. 1 Azide (2.5mM) did not inhibit CSF activity ( Fig. 2B ), excluding the source of the activity being a multicopper ferroxidase e.g. CP. The absence of CP activity in human CSF is in alignment with normal levels of CP (~1.5 µg/ml) 18 being <1% of those ! 6 found in serum (200-500µg/ml) 19 . Consistent with the previously reported level of CP in CSF, recombinant CP at this concentration (~2.5 µg/ml) is outside the active range of our assay (<20nM; Fig. S4 ). Our findings are similar to the activity that has been reported to arise from <10kDa species in CSF from healthy and sporadic Creutzfeldt-Jakob disease (sCJD) patients 14 , but at variance with a report that ferroxidase activity in CSF originates from CP 13 .
To identify whether the ferroxidase activity from the filtrate was of protein enzyme origin, fractionated serum and CSF were treated with proteinase K. In serum, the protease abolished the retentate activity, but had no effect on the filtrate activity ( Fig. 3A & S5A). Protease incubation with CSF had no effect on the total activity or the filtrate fraction ( Fig. 3B & S5B ).
The capacity for polyanions to oxidize iron and facilitate the incorporation of Fe 3+ into TF is a confounding factor in measuring enzymatic ferroxidase activity 1 . We quantified the polyanion content in serum and CSF to identify whether these could be a source of the apparent ferroxidation activity in the filtrates. Phosphate and citrate are prevalent polyanions to oxidize iron in biological samples. We found that phosphate levels were greater in serum ( Fig. 4Ai) whereas citrate levels were observed to be greater in CSF (Fig. 4Aii ). To highlight the polyanion influence on ferroxidase activity in CSF, variability in the combined phosphate and citrate levels within CSF filtrates was observed to correlate with activity as measured by Ferric gain (P=0.010, r 2 =0.465) and TF loading (P=0.006, r 2 =0.509) ( Fig. 4B ). Ferric gain assay identified that both phosphate (P=0.040, r 2 =0.391) and citrate (P=0.029, r 2 =0.363) contributed to this correlation ( Fig. S6A ) and a similar trend was observed with TF loading (Fig. S6B ).
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We applied our assays under physiological conditions to assay serum and serum fractions from AD patients (n=10) and age-matched healthy controls (n=10) ( Table   S1 ). Although activities in whole serum samples were not different in AD patients by either Ferric gain or TF loading assays (Fig. 5A ), there was a significant decrease in ferroxidase activity in the serum retentate fractions by these assays (Ferric gain -13%, TF loading -10%, Fig. 5A ). This is analogous with the ~10% decrease in ceruloplasmin specific activity reported in a larger sampling of AD compared to control sera 9 . There was no difference between the AD and control groups in the serum filtrate activity measured by either assay, consistent with the finding of no difference in either serum phosphate, citrate levels ( Fig. 5C ) or when these were combined (data not shown).
We also applied our assays under physiological conditions to evaluate CSF and CSF fractions from AD patients (n=10) and age-matched healthy controls (n=10) ( Table   S1 ). Total CSF and retentate samples were not altered in AD, but AD CSF filtrates had significantly decreased activity by both Ferric gain and TF loading assays (Fig.   5B ). With activity mostly originating from polyanions within the filtrate, citrate and phosphate levels were analysed but neither were altered in AD compared to healthy controls when measured individually ( Fig. 5C ) or in combination (data not shown).
Our data provide simultaneous analysis on all steps of iron oxidation in biological fluids under physiological conditions, relevant for neurological disorder screening.
Utilizing this assay confirms that serum activity largely resides in a >10kDa fraction that can be inhibited by azide, consistent with CP. In contrast, the majority of the activity in human CSF originates from the <10kDa fraction. Lack of a high molecular weight enzymatic activity is consistent with the low CP concentration reported in ! 8 CSF. We 1, 2 and others 14 The discovery that these disease associated changes in serum predominately originate from an azide inhibitable component suggests that while there is no detectable difference in serum copper or CP levels 19 , there may be less copper bound to CP in AD patients. This would be different to PD where a lower CP expression correlates with age of Parkinsonian onset 20 . Either a decreased copper-dependent activity of CP expression would likely cause the decreased iron saturation of TF recently reported for AD 21 . While the negligible ferroxidase activity in CSF is unaltered in AD, we found a decrease in iron oxidation mediated by small molecular weight species, similar to other neurodegenerative diseases such as sCJD and PD 13, 14 . We could not confirm that this change in CSF was attributable to decreased citrate and phosphate levels, and other small molecular weight molecules may contribute. Monitoring the activity in neurological conditions such as multiple sclerosis that have a reported CSF polyanion imbalance 22 may assist in identifying these other contributory small molecular weight molecules. The retentate fraction (>10kDa) was resuspended in Milli-Q® H 2 0 to a comparable volume as the filtrate (<10kda) (Fig.S1 ). The retentate was then washed once with the same volume of Milli-Q® H 2 0 to remove retained filtrate. In experimental conditions that required the elimination of protein enzymatic activity, samples were treated with 50µg/ml of proteinase-K overnight at 37 o C.
METHODS

Reagents
Ferroxidase assays. Assay conditions originally reported for in vitro analysis 1 were found to be optimal also for measuring activity from CSF and serum. Only the duration of the assay and the volume of CSF or concentration of serum required optimization (Fig. S2 ). As previously described 1 , preparation of apo-transferrin (apo-TF; >98% purity) and ferrous sulfate ( Difference between the means were calculated by one-way ANOVA followed by DunnettÕs test to confirm the existence of correlations between activity and polyanion concentration or between AD and healthy control. P<0.05 was taken to be statistically significant and results are expressed as the means ± SEM unless presented otherwise.
ÔFerric gainÕ plots represent the differential amount of Fe(III) that results from biological sample oxidation, ÔTransferrin loadingÕ identifies the amount of Fe 3+ that was loaded onto apo-transferrin and lastly ÔFerrous lossÕ illustrates the amount of Fe 2+ that remains from the conversion of Fe 2+ to Fe 3+ during the oxidation process by the sample. Conditions replicated from A were used to measure retentate and filtrate fractions of human CSF ferroxidase activity in the presence of sodium azide (2.5mM). C. 10 min after ferroxidase conversion remaining Fe 2+ was measured by ferene S in the absence (i) or presence (ii) of TF to confirm ferroxidase activity from CSF total, retentate and filtrate fractions. The same conditions as for serum were found to be optimal for CSF Conditions for carrying out the triplex assay in human serum were as optimized in Fig. 1. B . As with A, ferroxidase activity in AD CSF was compared to HC by Ferric Gain in the absence of TF (i) or apo-TF loading (ii) using the optimal conditions identified in Fig. 2 . C. Within the filtrate fraction found to contain non-enzymatic activity, phosphate (i) and citrate (ii) levels in AD were compared to HC in serum and CSF. Individual data points are means read in triplicates, each disease group are means ± S.E, with each group containing n= 10. *=P<0.05 as analysed by 2-tailed Ttest. 
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